Industry Sponsored Sessions Sunday, October 19, 2014 : UEG Week Final Programme
Transcription
Industry Sponsored Sessions Sunday, October 19, 2014 : UEG Week Final Programme
Sunday, October 19, 2014 Industry Sponsored Sessions : UEG Week Final Programme Industry Sponsored Sessions 345 UEG Week Final Programme : Industry Sponsored Sessions Sunday, October 19, 2014 Industry Sponsored Sessions Sunday, October 19, 2014 Industry Sponsored Session 16:15 – 17:45 Hall B When reflux symptoms persist despite PPI: What should we do? Industry Sponsored Session 16:15 – 17:45 Hall F2 Management of Colonic Diverticular Disease: Where is the evidence? (RB) (ALFA WASSERMANN S.p.A.) Chair: Heinz Hammer, Austria Chair: Carmelo Scarpignato, Italy Welcome and introductions Heinz Hammer, Austria Introductory remarks Carmelo Scarpignato, Italy Prevalence and burden of the problem Hashem El-Serag, USA Clinical picture and natural history Robin Spiller, United Kingdom Causes of these symptoms Daniel Sifrim, United Kingdom Symptomatology in IBS and DD: Is gut microbiota the missing link? Giovanni Barbara, Italy Assessing the patients Frank Zerbib, France Therapeutic advances Peter Bytzer, Denmark Question and answer session Industry Sponsored Session 16:15 – 17:45 Hall F1 Evolution in opioid-induced constipation management (AstraZeneca) Chair: Andrew Davies, United Kingdom Chair’s introduction Andrew Davies, United Kingdom Symptoms of opioid-induced constipation: is it more than reduced bowel movements? AsbjØrn Drewes, Denmark What are the burdens of opioid-induced constipation for the patient and healthcare professionals? Andrew Davies, United Kingdom Novel strategies for the treatment of opioid-induced constipation Jan Tack, Belgium Questions and answers Close Andrew Davies, United Kingdom 346 Therapeutic options for Diverticular Disease Fermin Mearin, Spain Conclusion Carmelo Scarpignato, Italy Industry Sponsored Session 18:00 – 19:30 Hall L/M Acid-related disorders: Myths and realities on formulations and PPI safety (Takeda Pharmaceuticals International) Chair: Colin Howden, USA Welcome and introductions Colin Howden, USA Benefits of orally dissolving PPI Richard Hunt, Canada Treating gastric acid related disorders with IV PPI David Metz, USA Update on drug-drug interactions Colin Howden, USA Q & A – Panel discussion Sunday, October 19, 2014 Industry Sponsored Sessions : UEG Week Final Programme Industry Sponsored Session 18:00 – 19:30 Hall N Revestive (teduglutide): A new treatment for short bowel syndrome Industry Sponsored Session 18:00 – 19:30 Hall B Optimizing care in Ulcerative Colitis – How can we raise the bar in 2015? (NPS Pharma International Limited) (AbbVie Inc.) Chair: Simon Gabe, United Kingdom Chair: Walter Reinisch, Austria Introduction Simon Gabe, United Kingdom Introduction Walter Reinisch, Austria Short bowel syndrome – A rare but complex condition Simon Gabe, United Kingdom The burden of ulcerative colitis – A progressive disease? Jean-Frédéric Colombel, USA Introducing teduglutide: MoA and clinical trial results Palle Jeppesen, Denmark Biologic therapy in ulcerative colitis – When to use and how to optimize? Shomron Ben-Horin, Israel Identifying suitable patients for teduglutide Simon Gabe, United Kingdom The evolution of clinical trials in ulcerative colitis Subrata Ghosh, Canada Starting patients on teduglutide, initial and medium term management Ulrich-Frank Pape, Germany Q & A and summary Walter Reinisch, Austria Real world experience: A longer term perspective Kishore Iyer, USA Q & A 347 UEG Week Final Programme : Industry Sponsored Sessions Monday, October 20, 2014 Industry Sponsored Sessions Monday, October 20, 2014 Industry Sponsored Session 07:00 – 08:00 Hall F1 The new era of biologic therapy in gastroenterology Industry Sponsored Session 18:00 – 19:30 Hall B Improving quality of care in IBD: Ideas worth sharing (Celltrion Healthcare) (AbbVie Inc.) Chairs:Walter Reinisch, Austria Clemens Dejaco, Austria Welcome and introduction Simon Travis, United Kingdom Welcome & Introduction Walter Reinisch, Austria Clemens Dejaco, Austria What doctors can learn from each other Stefan Larsson, Sweden Improvement of hospital-based care - 2014 report from KPMG Hilary Thomas, United Kingdom Gert van Assche, Belgium ‘Gold-Standard’ anti-TNF antibody therapy in IBD, Infliximab Walter Reinisch, Austria Case Presentation Part I Dong-Il Park, Republic of Korea Case Presentation Part II Jørgen Jahnsen, Norway Tailoring IBD care: Is there a recipe for success? Brian Feagan, Canada Remo Panaccione, Canada Q & A Discussion Summary & Close Walter Reinisch, Austria Clemens Dejaco, Austria Summary and close Simon Travis, United Kingdom Industry Sponsored Session 18:00 – 19:30 New horizons in IBD therapy Hall D (Takeda) Industry Sponsored Session 18:00 – 19:30 Hall C To treat. To cure. Sharing the journey to eradicate HCV (AbbVie Inc.) Chair: Herbert Tilg, Austria Chair: Markus Peck-Radosavljevic, Austria Chairman’s introduction: Opportunities for clinical success Herbert Tilg, Austria Samuel S. Lee, Canada Massimo Puoti, Italy Therapeutic approaches in IBD and treatment goals Stefan Schreiber, Germany New treatment options in IBD; today and the future Silvio Danese, Italy Panel discussion: Treatment decisionmaking in clinical practice Geert d’Haens, The Netherlands Questions and answers 348 Monday, October 20, 2014 Industry Sponsored Sessions : UEG Week Final Programme Industry Sponsored Session 18:00 – 19:30 Hall F1 Prokinetics in chronic constipation: The journey from clinical research to daily practice (Shire) Welcome and introductions Jan Tack, Belgium Prucalopride: Shaping the current treatment landscape in chronic constipation Jan Tack, Belgium The gastroenterologist’s case file: Challenges in chronic constipation diagnosis and treatment Yan Yiannakou, United Kingdom Prucalopride: What is beyond the horizon? Hubert Piessevaux, Belgium Q & A and panel discussion Jan Tack, Belgium Closing remarks Jan Tack, Belgium Industry Sponsored Session 18:00 – 19:30 Hall I/K Is blue-light laser imaging “Darwinism” in endoscopy? (Fujifilm Europe GmbH) Chairs:Horst Neuhaus, Germany Thierry Ponchon, France Paul Fockens, The Netherlands Thierry Ponchon, France Jacques Bergman, The Netherlands Mitsuhiro Fujishiro, Japan Yutaka Saito, Japan 349 UEG Week Final Programme : Industry Sponsored Sessions Tuesday, October 21, 2014 Industry Sponsored Sessions Tuesday, October 21, 2014 Industry Sponsored Session 07:00 – 08:00 Hall F1 Moving forward – New PPIs for today’s patients Industry Sponsored Session 18:00 – 19:30 Hall B Achieving long-term success: Continuous control of Ulcerative Colitis (Takeda) (MSD) Challenges facing today’s PPI patients Peter Malfertheiner, Germany Next steps in PPI development – Targeting the patients’ needs David C. Metz, USA Symptom relief – Today’s patients’ priority Joaquim P. Moraes-Filho, Brazil Industry Sponsored Session 18:00 – 19:30 Hall E Wheat bran fibre: And it’s role in gut health (Kellogg’s) Chair: Angie Jefferson, United Kingdom Dietary Fibre: What is it, how does it act and what forms are best for digestive health Kathryn O’Sullivan, Ireland Intact cereal dietary fibre and digestive health: A critical assessment of its role in the prevention and management of gut symptoms and disorders Jan de Vries, The Netherlands Digestive function during the menstrual cycle: Is there an association with fibre consumption? Louise Dye, United Kingdom The economics of constipation: A European review Kathryn O’Sullivan, Ireland Chair: Geert d’Haens, Belgium Welcome and opening remarks Geert d’Haens, Belgium From clinical trials to clinical practice: What are the unmet needs in the management of UC? Geert d’Haens, Belgium Achieving continuous disease control: What are the treatment options for UC? Walter Reinisch, Austria Leveraging our knowledge of UC: How can we best use our experience when selecting a treatment? Alessandro Armuzzi, Italy Panel discussion / Q & A Industry Sponsored Session 18:00 – 19:30 Hall F1 Cognitive impairment in liver cirrhosis: The differential diagnosis (Norgine) Chair: Sara Montagnese, Italy Welcome and objectives Sara Montagnese, Italy Liver cirrhosis: Patient’s voice Patient video HE practise guidelines: What do they mean for clinical practise Joost P.H. Drenth, The Netherlands THE EPHE STUDY: Epidemiology and diagnosis of hepatic encephalopathy Joachim Labenz, Germany Liver cirrhosis: Specialist care / differential diagnosis Sara Montagnese, Italy 350 Q/A and conclusions Tuesday, October 21, 2014 Industry Sponsored Sessions : UEG Week Final Programme Industry Sponsored Session 18:00 – 19:30 Hall G/H New insights into the clinical and economic impact of Saccharomyces boulardii in antibiotic-associated diarrhea (BIOCODEX) Chair: Philippe Marteau, France Introduction Awareness of probiotics: Survey of 10 countries Christian Boggio-Marzet, Argentina Saccharomyces boulardii impact on gut microbiota, antibiotic-associated diarrhea, and Clostridium difficile disease Ciaran Kelly, USA Effectiveness of Saccharomyces boulardii in reducing hospitalization costs related to antibiotic-associated diarrhea Sebastian Vermeersch, Belgium Q & A session Conclusion UEG thanks its longterm partners for their continuous support 351